Free Trial

Chris Raymond Analyst Performance

Analyst at Raymond James Financial

Chris Raymond is a stock analyst at Raymond James Financial, covering 7 publicly traded companies across a range of sectors. Over the past year, Chris Raymond has issued 8 stock ratings, including strong buy and buy recommendations. While full access to Chris Raymond's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Chris Raymond's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
8 Last 0 Years
Buy Recommendations
100.00% 8 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy87.5%7 ratings
Buy12.5%1 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

Out of 8 total stock ratings issued by Chris Raymond at Raymond James Financial, the majority (87.5%) have been Strong Buy recommendations, followed by 12.5% Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
85.7% of companies on NASDAQ
6 companies
NYSE
14.3% of companies on NYSE
1 company

Chris Raymond, an analyst at Raymond James Financial, currently covers 7 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Chris Raymond of Raymond James Financial specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
7 companies
100.0%

Chris Raymond's Ratings History at Raymond James Financial

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Biohaven Ltd. stock logo
BHVN
Biohaven
9/3/2025Upgrade$16.21Strong-Buy
Sionna Therapeutics, Inc. stock logo
SION
Sionna Therapeutics
9/2/2025Initiated Coverage$25.39$45.00Strong-Buy
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
9/2/2025Initiated Coverage$12.53$35.00Strong-Buy
Nuvalent, Inc. stock logo
NUVL
Nuvalent
9/2/2025Initiated Coverage$76.90$105.00Outperform
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
9/2/2025Initiated Coverage$33.93$80.00Strong-Buy
Kalaris Therapeutics Inc. stock logo
KLRS
Kalaris Therapeutics
9/2/2025Initiated Coverage$4.00Strong-Buy
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
9/2/2025Initiated Coverage$12.00$30.00Strong-Buy
Biohaven Ltd. stock logo
BHVN
Biohaven
9/2/2025Initiated Coverage$15.89$75.00Strong-Buy